Literature DB >> 12461497

The impact of early cystic fibrosis diagnosis on pulmonary function in children.

Sophia S Wang1, Leslie A O'Leary, Stacey C Fitzsimmons, Muin J Khoury.   

Abstract

OBJECTIVE: To investigate the impact of early diagnosis on pulmonary function in a large cohort of children with cystic fibrosis (CF). STUDY
DESIGN: CF cases identified from the CF Foundation National Patient Registry and diagnosed between 1982 and 1990 were categorized as: early asymptomatic diagnosis (EAD; n = 157), early symptomatic diagnosis (ESD; n = 227), later asymptomatic diagnosis (LAD; n = 161), and later symptomatic diagnosis (LSD; n = 3080). Early CF diagnosis was diagnosis before 6 weeks of age; later diagnosis was diagnosis at 6 weeks to 36 months of age, inclusive. Asymptomatic diagnosis included diagnosis by either family history, genotype, prenatally, or neonatally. Pulmonary function was measured as percentage of predicted forced expiratory volume in one second (FEV(1)).
RESULTS: There were no overall differences in pulmonary function among the 4 diagnostic groups. However, EAD cases born more recently (1987 or later) had a higher mean FEV(1) throughout the study, compared with the remaining diagnostic groups. For this later birth cohort, Cox regression analysis for those diagnosed later and/or symptomatically, demonstrated a 2-fold increase in risk (P =.06) for having moderate-to-severe pulmonary function (FEV(1) <70%) at ages 6 to 10 years, compared with EAD cases.
CONCLUSIONS: Children diagnosed with CF early, asymptomatically and more recently may have better pulmonary function throughout early childhood, probably as a result of improved CF treatments in recent years.

Entities:  

Mesh:

Year:  2002        PMID: 12461497     DOI: 10.1067/mpd.2002.129845

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  3 in total

1.  A novel lung disease phenotype adjusted for mortality attrition for cystic fibrosis genetic modifier studies.

Authors:  Chelsea Taylor; Clayton W Commander; Joseph M Collaco; Lisa J Strug; Weili Li; Fred A Wright; Aaron D Webel; Rhonda G Pace; Jaclyn R Stonebraker; Kathleen Naughton; Ruslan Dorfman; Andrew Sandford; Scott M Blackman; Yves Berthiaume; Peter Paré; Mitchell L Drumm; Julian Zielenski; Peter Durie; Garry R Cutting; Michael R Knowles; Mary Corey
Journal:  Pediatr Pulmonol       Date:  2011-04-01

Review 2.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

Review 3.  Cystic fibrosis on the African continent.

Authors:  Cheryl Stewart; Michael S Pepper
Journal:  Genet Med       Date:  2015-12-10       Impact factor: 8.822

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.